Cassia Capital Partners LLC Acquires 1,747 Shares of Johnson & Johnson (NYSE:JNJ)

Cassia Capital Partners LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,285 shares of the company's stock after buying an additional 1,747 shares during the period. Johnson & Johnson comprises about 0.8% of Cassia Capital Partners LLC's holdings, making the stock its 25th largest position. Cassia Capital Partners LLC's holdings in Johnson & Johnson were worth $1,208,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson during the fourth quarter worth about $290,000. Capital & Planning LLC increased its holdings in Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after buying an additional 183 shares during the last quarter. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Johnson & Johnson during the fourth quarter worth about $85,886,000. Finally, Hudson Value Partners LLC increased its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Raymond James Financial reduced their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $0.14 during mid-day trading on Wednesday, hitting $152.33. 7,149,773 shares of the company traded hands, compared to its average volume of 8,004,092. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market cap of $366.52 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a fifty day moving average price of $153.95 and a 200-day moving average price of $153.67.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.